PANLAR's Latin American Registry of Rheumatic Patients Treated With Jak Inhibitors

Launched by LIGA PANAMERICANA DE ASOCIACIONES DE REUMATOLOGIA (PANLAR) · Mar 26, 2021

Keywords

ClinConnect Summary

There is scarce data on the real-world safety and effectiveness of Jak in Latin America. This registry will provide reliable data on the use of JAKi in LA, as will be a prospective study involving carefully selected rheumatologists and centers. Soon, a good number of copies of original JAKi will be available in LA, and it is important to keep track of the safety and effectiveness of this drugs in the real world.

The primary objective of the registry is to prospectively study the comparative safety and comparative effectiveness of approved Jak Inhibitors treatment for RA-PsA-SpA in a cohort...

Gender

ALL

Eligibility criteria

• • To be eligible for enrollment into the PREJAK Registry, a patient must satisfy all of the inclusion criteria and none of the exclusion criteria listed below.
• • Inclusion Criteria
• The patient must be:
• 1. One of the following:
• • 1. Diagnosis with rheumatoid arthritis (RA) and initiating (prescribed or starting) a Januse Kinase inhibitors (JAKi) for the treatment of RA at the enrollment visit.
• • 2. Meet the ASAS criteria for axial spondyloarthritis (AxSpA), including radiographic or non-radiographic, and initiating (prescribe or starting) a JAKi for the treatment of AxSpA at the enrollment visit.
• • 3. Diagnosis with psoriatic arthritis (PsA) and initiating (prescribed or starting) a Januse Kinase inhibitors (JAKi) for the treatment of PsA at the enrollment visit.
• • 2. At least 18 years age or older
• • 3. Able and willing to provide written consent
• Exclusion Criteria:
• • Patients who do not wish to participate or are unable to give informed consent